Anti-TNF | |||||||
---|---|---|---|---|---|---|---|
All (n = 4736) | ETA (n = 934) | INF (n = 561) | ADA (n = 1218) | GOL (n = 858) | TOC (n = 1165) | P value | |
Age (years), mean ± SD | 54.2 ± 13.3 | 53.4 ± 14.3 | 56.2 ± 12.7 | 52.3 ± 13.6 | 55.0 ± 12.8 | 55.5 ± 12.6 | < 0.0001 |
Women, n (%) | 3841 (81.1) | 747 (80.0) | 471 (84.0) | 947 (77.8) | 708 (82.5) | 968 (83.1) | 0.0021 |
Combination of DMARDs, n (%)a | |||||||
Methotrexate | 3953 (83.5) | 768 (82.2) | 485 (86.5) | 1047 (86.0) | 772 (90.0) | 881 (75.6) | < 0.0001 |
Leflunomide | 678 (14.3) | 89 (9.5) | 144 (25.7) | 169 (13.9) | 73 (8.5) | 203 (17.4) | < 0.0001 |
Tacrolimus | 212 (4.5) | 36 (3.9) | 15 (2.7) | 49 (4.0) | 33 (3.9) | 79 (6.8) | 0.0003 |
Glucocorticoid use, n (%)a | 4143 (87.5) | 817 (87.5) | 486 (86.6) | 1081 (88.8) | 672 (78.3) | 1087 (93.3) | < 0.0001 |
LTBI prophylaxis, n (%) | 1168 (24.7) | 279 (29.9) | 113 (20.1) | 298 (24.5) | 182 (21.2) | 296 (25.4) | < 0.0001 |
Entry year, n (%) | < 0.0001 | ||||||
2013 | 85 (1.8) | 16 (1.7) | 18 (3.2) | 14 (1.2) | 11 (1.3) | 26 (2.2) | |
2014 | 1208 (25.5) | 321 (34.4) | 187 (33.3) | 271 (22.3) | 182 (21.2) | 247 (21.2) | |
2015 | 956 (20.2) | 181 (19.4) | 127 (22.6) | 225 (18.5) | 179 (20.9) | 244 (20.9) | |
2016 | 1002 (21.2) | 164 (17.6) | 100 (17.8) | 291 (23.9) | 174 (20.3) | 273 (23.4) | |
2017 | 1033 (21.8) | 163 (17.5) | 89 (15.9) | 276 (22.7) | 222 (25.9) | 283 (24.3) | |
2018 | 452 (9.5) | 89 (9.5) | 40 (7.1) | 141 (11.6) | 90 (10.5) | 92 (7.9) |